Schizophrenia News and Research

Latest Schizophrenia News and Research

PKCI/HINT1 gene associated with mood regulation

Removing the PKCI/HINT1 gene from mice has an anti-depressant-like and anxiolytic-like effect. Researchers writing in the open access journal BMC Neuroscience applied a battery of behavioral tests to the PKCI/HINT1 knockout animals, concluding that the deleted gene may have an important role in mood regulation.

13 Nov 2009

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer's disease (AD) and schizophrenia.

13 Nov 2009

ARYx Therapeutics announces operating results for the third quarter of 2009

ARYx Therapeutics, Inc. today reported results of operations and provided a general business update for the third quarter ended September 30, 2009.

12 Nov 2009

Results from an analysis emphasizes the financial burden of SMI on the criminal justice and HHS systems

Results from a large, retrospective analysis of inmates with a serious mental illness (SMI) underscores the financial burden of mental illness on the criminal justice and health and human services (HHS) systems, and may provide useful information to policy makers.

12 Nov 2009

Academic Health Center receives 128 grants totaling nearly $35 million in federal stimulus money

Academic Health Center scientists, physicians, and research centers have attracted 128 grants totaling nearly $35 million in federal stimulus money (as of Nov. 10) since the American Recovery and Reinvestment Act was approved in February 2009. This will result in a total economic impact of more than $105 million; according to the National Institutes of Health, $1 of research funding multiplies to more than $2 of goods and services in the economy.

11 Nov 2009

Re-classification of cannabis will have minimal impact on incidence of psychosis says study

The research follows last year’s decision by the UK government to reclassify the drug from class C to class B, partly out of concerns that cannabis, especially the more potent varieties, may increase the risk of schizophrenia in young people. However, the evidence for the relationship between cannabis and schizophrenia or psychosis remains controversial.

5 Nov 2009

Health care jobs plentiful but tough to get

While health care jobs are plentiful, "getting one is hard work," The Associated Press/The News-Sentinel reports. "Many people who have lost jobs to the recession may find a cure for unemployment in the health care field," and the demand for nurses, specialists and technicians is strong

4 Nov 2009

Molecular imaging pinpoints inflammation in the brains of schizophrenics and migraine sufferers

Inflammatory response of brain cells-as indicated by a molecular imaging technique-could tell researchers more about why certain neurologic disorders, such as migraine headaches and psychosis in schizophrenic patients, occur and provide insight into how to best treat them, according to two studies published in the November issue of the Journal of Nuclear Medicine.

31 Oct 2009

NARSAD to present Productive Lives Award to Randy Lewis

Randy Lewis, the SVP of supply chain and logistics for Walgreens, the nation’s largest drugstore chain, will receive the first ever Productive Lives Award from NARSAD tonight at its 22nd annual New York Awards Dinner at the Pierre Hotel.

30 Oct 2009

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that it has implemented a staffing plan to operate the company that anticipates licensing its lead development programs and resuming development of earlier stage product candidates.

30 Oct 2009

Positive top-line results from Phase IIb clinical trial of cariprazine announced

Forest Laboratories, Inc. and Gedeon Richter Plc today announced positive top-line results from a Phase IIb clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of acute exacerbation of schizophrenia.

29 Oct 2009

CAMH Foundation receives $5 million gift for mental health research

An extraordinary gift of $5 million from Mr. G. Raymond Chang, Chancellor of Ryerson University and Chair of CI Financial, will go toward furthering research and education about the treatment of mental health and addictions, the Centre for Addiction and Mental Health (CAMH) Foundation announced today.

29 Oct 2009

Modern functional brain imaging techniques can be a dynamic process of looking at psychopathology

Modern functional brain imaging techniques are available to psychiatrists and are promising modern-day 'telescopes' to explore in vivo brain activity. Modern psychiatric neuroimaging suggests that only phenomena that may be seen and mathematically computed throughout the scan are real.

28 Oct 2009

Scientists test rapamycin's effectiveness at rescuing impaired nerve cells

Johns Hopkins scientists report having used a commercially available drug to successfully "rescue" animal brain cells that they had intentionally damaged by manipulating a newly discovered gene that links susceptibility genes for schizophrenia and autism.

28 Oct 2009

Susceptibility to schizophrenia and autism may have common genetic fingerprints, says researchers

28 Oct 2009

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Many pediatric and adolescent patients who received second-generation antipsychotic medications experienced significant weight gain, along with varied adverse effects on cholesterol and triglyceride levels and other metabolic measures, according to a study in the October 28 issue of JAMA.

28 Oct 2009

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Alkermes, Inc. today announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetic effects of a single oral administration of five doses of ALKS 37 in approximately 40 healthy volunteers.

27 Oct 2009

New therapy for decreasing anxiety and improving psychological well-being in children

A group of investigators of the University of Bologna suggest a new way of approaching emotional disturbances in children by improving their psychological well-being. The study is published in the current issue of Psychotherapy and Psychosomatics.

27 Oct 2009

Discovery of molecular pathway in brain may reverse cognitive impact of sleep deprivation

A research collaboration led by biologists and neuroscientists at the University of Pennsylvania has found a molecular pathway in the brain that is the cause of cognitive impairment due to sleep deprivation.

27 Oct 2009

Major fundraising initiative launched for Rett syndrome research

Inspired by recent breakthroughs in research, today the International Rett Syndrome Foundation (IRSF) announced a major fundraising initiative entitled Research to Reality: Funding Progress. Funds raised by the campaign are earmarked to accelerate the progress of crucial research, and bring promise to reality. Country music sensation Clint Black, whose niece Courtney lost her battle with Rett syndrome in 2003 at age 16, will serve as Honorary Chair of the campaign.

26 Oct 2009

Schizophrenia News and Research

Latest Schizophrenia News and Research

PKCI/HINT1 gene associated with mood regulation

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

ARYx Therapeutics announces operating results for the third quarter of 2009

Results from an analysis emphasizes the financial burden of SMI on the criminal justice and HHS systems

Academic Health Center receives 128 grants totaling nearly $35 million in federal stimulus money

Re-classification of cannabis will have minimal impact on incidence of psychosis says study

Health care jobs plentiful but tough to get

Molecular imaging pinpoints inflammation in the brains of schizophrenics and migraine sufferers

NARSAD to present Productive Lives Award to Randy Lewis

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

Positive top-line results from Phase IIb clinical trial of cariprazine announced

CAMH Foundation receives $5 million gift for mental health research

Modern functional brain imaging techniques can be a dynamic process of looking at psychopathology

Scientists test rapamycin's effectiveness at rescuing impaired nerve cells

Susceptibility to schizophrenia and autism may have common genetic fingerprints, says researchers

Pediatric and adolescent patients who receive antipsychotic medications experience weight gain

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

New therapy for decreasing anxiety and improving psychological well-being in children

Discovery of molecular pathway in brain may reverse cognitive impact of sleep deprivation

Major fundraising initiative launched for Rett syndrome research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Schizophrenia News and Research

Latest Schizophrenia News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in